Precision Cardiac Disease Modeling with the Curi Engine™

As American Heart Month concludes and Rare Disease Day approaches, the conversation shifts from awareness to action, and specifically how we model and treat the most complex cardiac diseases with precision and confidence.

At Curi Bio, we focus on advancing cardiac drug discovery through human-relevant, function-first disease models built on engineered heart tissues (EHTs).

From hypertrophic cardiomyopathy (HCM) and arrhythmogenic cardiomyopathy (ARVC) to rare channelopathies and cardiotoxicity risk assessment, our ecosystem is designed to reveal true human cardiac phenotypes— reproducibly and at scale.

The Biological Foundations of Functional Cardiac Modeling

Robust cardiac modeling begins with high-quality biology.

• High Purity Cardiomyocytes and Validated Cardiac Media
  Functional readouts like contractile force, beat rate, rhythm stability—reflect true cardiomyocyte behavior without confounding non-cardiac cell artifacts and with optimized performance and amplified effect sizes from Curi Bio’s cardiac media.

• Functional Tissues
  Cells integrate seamlessly into 3D engineered heart tissues, forming electrically and mechanically coupled constructs that recapitulate adult-like cardiac physiology.

• Sensitivity for Rare and Genetic Disease Signals
  In models of HCM as well as ARVC, our EHT ecosystem enables detection of subtle arrhythmic phenotypes, contractile deficits, and therapeutic rescue effects.

Functional Phenotyping at Scale

Curi Bio’s integrated hardware and software ecosystem enables quantitative cardiac functional analysis across discovery workflows:

• Mantarray™ Platform: Real-time, label-free contractile force measurement from 3D EHTs to assess pacing fidelity, force–frequency relationships, and arrhythmia susceptibility

• Nautilai™ Imaging: Complementary optical calcium and voltage assessments for comprehensive electrophysiological profiling

• Pulse™ Software Analytics: Automated detection of contractile function, irregular waveforms, beat-to-beat variability, and dose-dependent functional shifts

A Platform Built for Every Heart

Curi Bio’s integrated cardiac ecosystem enables rapid and flexible disease modeling whether through siRNA-mediated knockdown, gene editing, or patient-specific iPSC lines, supports mechanistic cardiotoxicity screening, gene therapy validation, and biologics development. By combining 3D EHTs with quantitative, real-time functional analytics, researchers can capture subtle contractile and arrhythmic phenotypes across acute and longitudinal study designs.

The result is scalable, human-relevant cardiac functional data that strengthens translational confidence and accelerates the path from discovery to clinical impact.

Contact us to learn more about how we can accelerate your decision-driving data today.